EZH2 inhibitors for treating lymphoma
First Claim
Patent Images
1. A method for treating non-Hodgkin'"'"'s lymphoma (NHL) comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the NHL is primary mediastinal large B-cell lymphoma (PMBCL), and wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
19 Citations
19 Claims
- 1. A method for treating non-Hodgkin'"'"'s lymphoma (NHL) comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the NHL is primary mediastinal large B-cell lymphoma (PMBCL), and wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
Specification